Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sezary Syndrome 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Hodgkin Disease 1 Carcinoma, Hepatocellular 1

Interventions

Brentuximab Vedotin 27 pembrolizumab 13 Nivolumab 11 Dacarbazine 8 Vinblastine 7 Doxorubicin 7 Gemcitabine 6 Bendamustine Hydrochloride 6 plerixafor 5 fludarabine 4 Rituximab 4 Granulocyte Colony-Stimulating Factor 4 Cyclophosphamide 4 Azacitidine 4 abexinostat 3 Melphalan 3 Filgrastim 3 Etoposide 3 Busulfan 3 Bleomycin 3 umbralisib 2 relatlimab 2 pegfilgrastim 2 mocetinostat 2 itacitinib 2 givinostat hydrochloride 2 givinostat 2 fludarabine phosphate 2 durvalumab 2 cc-486 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hodgkin Disease × resminostat × Clear all

NCT01037478 2014-01-16

SAPHIRE

4SC AG

Phase 2 Completed

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡